Phaseline

Companies › Laboratorio Farmaceutico SIT srl

Laboratorio Farmaceutico SIT srl: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BUCCALIN®
Oral bacterial vaccine containing Streptococcus pneumoniae (types I, II, III), Streptococc
–Phase 4Respiratory InfectionApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06736288BUCCALIN®Phase 4Respiratory InfectionInfectious diseaseApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx Jiangxi Qingfeng Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.